Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPX-501 T Cell Infusion for Recurrent/MRD Hematologic Malignancies Post-Transplant
NCT02477878Phase 1Active, not recruiting
- Sponsor
- Bellicum Pharmaceuticals, Inc.
- Start
- Jul 2016
- Primary completion
- Jan 2020
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rivogenlecleucel in leukemia, myelodysplastic syndrome (MDS), lymphoma and 1 more, sponsored by Bellicum Pharmaceuticals, Inc. Primary endpoints: BPX-501 Safety at Month 24, Rimiducid Safety at Month 24 and 3 more. Started Jul 2016; status: active, not recruiting.
02
Drugs
rivogenlecleucel
03
Conditions
leukemiamyelodysplastic syndrome (MDS)lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT02477878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02477878.